Hoth Therapeutics Inc (nasdaq:HOTH) Share Price

Company Profile

Business description
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Contact
1177 Avenue of the Americas
5th Floor, Suite 5066
New YorkNY10036
USA
T: +1 646 756-2997
https://www.hoththerapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3

Recommended

Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.

Rachel Schlueter | 06 March 2026

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Tyger Fitzpatrick | 06 March 2026

How the most traded shares stack up against our analysts views.

Tyger Fitzpatrick | 04 March 2026

Index	Last price	Change	% Change
All Ordinaries	9,085.10	36.30	0.40%
CAC 40	7,993.49	174.24	-2.13%
DAX 40	23,591.03	224.72	-0.94%
Dow JONES (US)	47,501.55	453.19	-0.95%
FTSE 100	10,275.43	138.51	-1.33%
HKSE	25,768.40	447.06	1.77%
NASDAQ	22,387.68	361.31	-1.59%
Nikkei 225	55,620.84	342.78	0.62%
NZX 50 Index	13,519.35	98.54	-0.72%
S&P 500	6,740.02	90.69	-1.33%
S&P/ASX 200	8,851.00	25.80	0.29%
SSE Composite Index	4,124.19	15.63	0.38%